Sagent Pharmaceuticals Initiates Nationwide Class II Recall of Methylprednisolone Acetate Injectable Suspension Due to Particulate Matter
Sagent Pharmaceuticals has initiated a nationwide Class II recall for 14,360 vials of Methylprednisolone Acetate Injectable Suspension due to black particulate matter. This voluntary action, affecting product manufactured in India, necessitates immediate supply chain and procurement review. Regulatory affairs must assess compliance, while business development monitors market shifts for this critical corticosteroid.
Recall Details: Sagent Pharmaceuticals Initiates Nationwide Class II Recall
Sagent Pharmaceuticals, based in Schaumburg, Illinois, has initiated a voluntary, nationwide Class II recall for specific lots of its Methylprednisolone Acetate Injectable Suspension, USP. This critical regulatory action, identified as recall number D-0499-2024, commenced on April 25, 2024, with the FDA classifying it on May 15, 2024. The recall targets 14,360 vials of the 400 mg per 10 mL (40 mg per mL) multi-dose product, distributed across the United States. The primary reason for this recall is the potential presence of black particulate matter within the drug product. For procurement directors and supply chain VPs, this necessitates an immediate inventory assessment to identify and quarantine affected lots 5100186, 5100187, 5100188, and 5100189, all expiring January 31, 2025. The Class II classification indicates a remote probability of serious adverse health consequences, but temporary or medically reversible adverse effects are possible. This demands swift action to prevent patient exposure. Regulatory affairs heads must ensure all recall procedures are meticulously followed, including communication with healthcare providers and managing product returns, to mitigate compliance risks. The product, NDC 25021-820-10, is a human prescription drug administered via intra-articular, intralesional, intramuscular, intrasynovial, and soft tissue routes.
Product and Manufacturing Origin: Methylprednisolone Acetate Supply Chain Implications
The recalled Methylprednisolone Acetate Injectable Suspension is a critical corticosteroid, widely utilized for its anti-inflammatory and immunosuppressive properties across various therapeutic areas, including dermatology, musculoskeletal conditions, and systemic hormone regulation. Sagent Pharmaceuticals, the recalling firm from Schaumburg, Illinois, markets this product under ANDA201835. A key detail for supply chain and business development executives is that while Sagent is the listed marketer for the U.S. market, the product description explicitly states "Made in India." This indicates manufacturing occurs at an overseas facility, likely under a contract manufacturing arrangement. This geographical separation introduces complexity for quality oversight and supply chain resilience. Procurement directors must scrutinize quality agreements with Sagent and any underlying contract manufacturers to ensure robust quality control for sterile injectable products, where particulate matter poses significant risks. The HSN code associated with Methylprednisolone Acetate is 29372900. Regulatory affairs heads should evaluate recall implications on future import activities and the need for enhanced due diligence on foreign manufacturing sites supplying the U.S. market. Understanding the origin of such quality deviations is paramount for preventing recurrence and safeguarding product integrity.
Supply Chain Exposure: Impact on Downstream Formulators and Healthcare Providers
The nationwide distribution of Sagent Pharmaceuticals' Methylprednisolone Acetate Injectable Suspension means healthcare providers, hospitals, and pharmacies across the United States are potentially impacted by this Class II recall. With 14,360 vials of the 400 mg per 10 mL strength affected, the immediate concern for supply chain VPs is potential localized shortages of this essential corticosteroid. While the FDA's Class II designation suggests a remote probability of serious adverse health consequences, particulate matter in injectables can lead to adverse events like venous emboli, phlebitis, or allergic reactions, directly affecting patient safety. For procurement directors, assessing exposure involves identifying existing stock and understanding consumption rates and lead times for alternatives. Business development executives should recognize that such recalls can create temporary market vacuums, presenting opportunities for competitors with robust quality systems. Regulatory affairs heads must be prepared for increased scrutiny from healthcare institutions regarding product quality and supplier reliability. The recall underscores the importance of supplier diversification and continuous quality monitoring, especially for high-volume, multi-dose injectable products integral to various medical treatments. Proactive communication and rapid replacement strategies are essential to minimize disruption.
Alternative Suppliers for Methylprednisolone Acetate
In response to Sagent Pharmaceuticals' recall of Methylprednisolone Acetate Injectable Suspension, procurement directors must swiftly identify and qualify alternative suppliers to mitigate potential supply disruptions. While the ChemLifeIntel Knowledge Graph details Sagent's broader product portfolio, it does not specifically list alternative suppliers for Methylprednisolone Acetate itself. However, the KG identifies several companies as general alternative suppliers for Sagent's overall product lines, which may or may not produce this specific corticosteroid. These include NorthStar Rx, Indoco Remedies, SYMBIOTICA SPECIALITY INGREDIENTS SDN BHD, Armas Pharmaceuticals (India), Apotex (Canada), Sanofi-Aventis U S (France), Advagen Pharma, and Willow Birch Pharma. For supply chain VPs, the immediate task involves contacting these potential suppliers to ascertain their capacity, inventory, and qualification timelines for Methylprednisolone Acetate. Given the "Made in India" origin of the recalled product, Armas Pharmaceuticals, also based in India, could be a relevant point of inquiry, though rigorous due diligence on their manufacturing quality and regulatory compliance is paramount. Regulatory affairs heads must be prepared to expedite the qualification process for any new supplier, ensuring their products meet FDA standards (ANDA201835) and integrate seamlessly into the U.S. distribution network. Business development executives should monitor market dynamics, as shifts in supplier preference could lead to significant long-term contract opportunities for agile, compliant manufacturers.
Regulatory Context and Risk Profile for Sagent Pharmaceuticals
Sagent Pharmaceuticals, a U.S.-based manufacturer from Schaumburg, Illinois, currently holds a "low" risk band according to ChemLifeIntel's assessment. This classification typically indicates a strong compliance record, making the Class II recall of Methylprednisolone Acetate Injectable Suspension a notable event. The company's extensive product portfolio spans critical therapeutic areas, including anti-infectives, oncology, and central nervous system drugs. This broad market presence means any quality deviation, even for a single product, can draw significant regulatory attention and impact confidence across its diverse offerings. For regulatory affairs heads, this recall underscores that a "low" risk band is not a guarantee against quality issues, particularly with third-party manufacturing, as suggested by the "Made in India" label. The FDA's ongoing monitoring of this voluntary, firm-initiated recall (D-0499-2024) will assess Sagent's corrective and preventive actions (CAPA) for the particulate matter issue. Procurement directors and quality assurance teams must reinforce due diligence, extending beyond initial supplier qualification to continuous oversight of all manufacturing partners, especially internationally. This event serves as a reminder that robust quality management systems are critical for maintaining market access and protecting brand reputation, regardless of historical risk profile.
Immediate Actions and Future Outlook for Supply Stability
The ongoing Class II recall of Sagent Pharmaceuticals' Methylprednisolone Acetate Injectable Suspension demands immediate and coordinated action from all stakeholders. Procurement directors must prioritize identifying and segregating all affected lots (5100186, 5100187, 5100188, 5100189) with the January 31, 2025, expiration date. Communication with Sagent Pharmaceuticals, Schaumburg, IL, is essential for product return logistics and securing replacement inventory. Given the product's critical nature as a corticosteroid, any delay in securing alternative supply could lead to treatment disruptions nationwide. Supply chain VPs should activate contingency plans, exploring expedited shipping and engaging with potential alternative suppliers to minimize lead times. The "Made in India" origin suggests Sagent will need to conduct a thorough root cause analysis at the manufacturing site to identify the source of black particulates and implement comprehensive corrective and preventive actions. Regulatory affairs heads must anticipate potential increased FDA scrutiny on Sagent's quality systems, particularly concerning contract manufacturing oversight. While voluntary, failure to adequately address underlying quality issues could lead to further regulatory actions. Business development executives should monitor market shifts, positioning their organizations to fill emerging gaps with compliant, high-quality products, ensuring long-term supply stability for this crucial molecule.